Moskowitz, A. J., Koch, R., Mehta-Shah, N., Myskowski, P., Kheterpal, M., Dogan, A., … Horwitz, S. M. (2017). In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. In BLOOD (Vol. 130).

Moskowitz, Alison J., Raphael Koch, Neha Mehta-Shah, Patricia Myskowski, Meenal Kheterpal, Ahmet Dogan, Theresa Davey, et al. “In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma.” In BLOOD, Vol. 130, 2017.

Moskowitz AJ, Koch R, Mehta-Shah N, Myskowski P, Kheterpal M, Dogan A, et al. In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. In: BLOOD. 2017.

Moskowitz, Alison J., et al. “In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma.” BLOOD, vol. 130, 2017.

Moskowitz AJ, Koch R, Mehta-Shah N, Myskowski P, Kheterpal M, Dogan A, Davey T, Galasso N, Evan M, Shah M, Ganesan N, Lubin L, Kim YH, Khodadoust M, Almazan T, Dai J, Jacobsen ED, Weinstock DM, Horwitz SM. In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. BLOOD. 2017.